Revolutionizing Immuno-Oncology: Clasp Therapeutics Secures $150M in Series A Funding

Clasp Therapeutics is making waves in the field of immuno-oncology with its groundbreaking approach to creating next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations. The company has successfully raised an impressive $150 million in a recent funding round, a testament to the confidence investors have in its innovative platform. This substantial investment reflects Clasp’s commitment to developing personalized, off-the-shelf therapeutics that cater to the unique genetic makeup of patients' tumors and the specific characteristics of their immune systems, particularly for hard-to-treat cancers that have long posed challenges in effective treatment. Founded in March 2024 and based in Cambridge, MA, and Rockville, MD, Clasp is built on pioneering research from renowned experts Bert Vogelstein and Drew Pardoll at Johns Hopkins University. The funding will empower Clasp to accelerate its research and development efforts, driving forward its mission to revolutionize cancer treatment through precision medicine. With backing from notable life sciences investors including Catalio Capital Management, Third Rock Ventures, and Novo Holdings, Clasp is poised to make a significant impact in the oncology landscape. By integrating state-of-the-art science with patient-centric approaches, Clasp Therapeutics aims not only to enhance the efficacy of cancer treatments but also to bring hope to patients battling with some of the most challenging cancers today. To learn more about the company and its groundbreaking work, please visit www.clasptx.com.